|Bid||46.62 x 800|
|Ask||49.95 x 1400|
|Day's Range||46.80 - 48.49|
|52 Week Range||35.04 - 64.48|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||4.34|
|Earnings Date||Feb 24, 2020 - Feb 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.27|
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences:
SAN DIEGO, Nov. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) was honored by the California Life Sciences Association (CLSA) with the Pantheon 2019 DiNA™ Deal of the Year Award. The Pantheon DiNA Awards are intended to recognize significant advancements in the California life sciences sector and celebrate the contributions and achievements of leading life sciences innovators in the state. When we realized that ralinepag had the potential to truly transform the treatment of PAH, we had to make the best decision for patients.
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the first patient has been dosed in a double-blind, randomized, placebo controlled, multi-center Phase 3 clinical study to evaluate the efficacy and safety of etrasimod for induction and maintenance of treatment in subjects with moderately to severely active ulcerative colitis (UC). Etrasimod is a next generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena Pharmaceuticals, Inc. (ARNA), and designed for optimized pharmacology and engagement of S1P receptor 1, 4 and 5 that may lead to an improved efficacy and safety profile.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shareholders might be concerned after seeing the share price drop 12% in the...
- Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion ...
SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of etrasimod in healthy adult male volunteers. "Results from this human mass balance study confirm that etrasimod is slowly and extensively metabolized via multiple metabolic pathways and demonstrate no exposure from any major metabolites. Additionally, multiple metabolic pathways for etrasimod significantly reduces the likelihood of any unwanted potential drug-drug interactions," said Preston Klassen, MD, MHS, Executive Vice President, Head of Research & Development at Arena.
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor conferences: Credit ...
SAN DIEGO , Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019 ...
SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the first subject has been dosed in the Phase 2 ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis (AD). "I am pleased that Arena is currently enrolling patients in its Phase 2 ADVISE study, advancing an oral agent with a novel mechanism of action for the potential treatment of atopic dermatitis," said Jonathan I. Silverberg, MD, PhD, MPH, Associate Professor of Dermatology, Director of Clinical Research, and Director of Patch Testing, at the George Washington University School of Medicine and Health Sciences. "The decision to move into dermatology, and specifically atopic dermatitis, is founded on scientific, preclinical and early clinical supporting evidence," stated Preston Klassen, MD, MHS, Executive Vice President, Head of Research and Development at Arena.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of June 28. In this […]
SAN DIEGO, Calif., Oct. 22, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 25th Annual United European Gastroenterology (UEG) Week. Etrasimod has therapeutic potential in immune and inflammatory-mediated diseases such as ulcerative colitis, Crohn's disease, and atopic dermatitis.
- New open-label extension data from the Phase 2 OASIS trial for etrasimod in ulcerative colitis - Arena sponsored breakfast symposium: Will oral therapies change the IBD treatment landscape? - Visit Arena ...
Every investor in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should be aware of the most powerful shareholder groups...
SAN DIEGO, Calif. , Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective ...
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer of Arena, will present a corporate update ...
SAN DIEGO , Sept. 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate ...
EVP, General Counsel & Sec of Arena Pharmaceuticals Inc (30-Year Financial, Insider Trades) Steven W Spector (insider trades) sold 44,084 shares of ARNA on 09/10/2019 at an average price of $50.59 a share. Continue reading...
SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn's disease (CD), as well as in programs for other indications such as atopic dermatitis.
The Major League Baseball is letting players smoke marijuana after the sports company removed the substance from its list of drugs and abuse. Yahoo Finance’s Julie Hyman, Dan Roberts, Brian Cheung and Pras Subramanian discuss on On The Move.